Trial Profile

A Phase 1, First Time in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NST 6179 in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Orziloben (Primary)
Indications Intestinal failure; Liver disorders; Short bowel syndrome
Focus Adverse reactions; First in man
Sponsors NorthSea Therapeutics

Most Recent Events

05 Jan 2023 According to Northsea Therapeutics media release, the company anticipates to progress to Phase II in 1st half of 2023.
01 Dec 2022 Status changed from recruiting to completed.
02 Feb 2022 According to a NorthSea Therapeutics media release, the company has initiated this study. Final results from this study is expected in the Q3 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com